Summary
The product STAN, manufactured by Driada Medical, underwent rigorous testing to verify its active ingredient and dosage accuracy. The sample, identified by batch number 969737, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality testing. The analysis confirmed the presence of stanozolol as the active ingredient, with a measured concentration of 9.96 mg per pill, closely aligning with the labeled specification of 10 mg per pill. This represents a 0.4% variance, demonstrating that the product is accurately dosed as per its specification.
The testing was commissioned and funded by Driada Medical, with the analysis completed on 28 February 2022. The sample was retested twice to ensure accuracy. Readers are encouraged to critically assess these results due to the manufacturer’s involvement in funding and submitting the sample. This report is published to support harm reduction and provide transparency for consumers.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: STAN
- Active Ingredient: Stanozolol
- Batch Number: 969737
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #18695
- Testing Ordered: 21 February 2022
- Sample Received: 22 February 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 10 mg per pill (as stated on the label)
- Measured Concentration: 9.96 mg per pill
- Accuracy: 99.6% (0.4% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/18695_R9NHIX9LWAZW
- Originally Published: https://thinksteroids.com/community/posts/2920247/
Evaluation of Manufacturer-Funded Testing
This analysis was funded and submitted by Driada Medical, warranting careful consideration of potential biases. While manufacturer-funded testing can raise concerns about selective sample submission, Janoshik Analytical’s transparency and reputation for rigorous testing lend credibility to the findings. The additional retesting adds a layer of verification. However, independent third-party testing is always recommended to corroborate results fully.
Conclusion
The analysis confirms that STAN is accurately dosed, with a measured concentration of 9.96 mg per pill, reflecting a 0.4% variance from the labeled specification of 10 mg per pill. This minor deviation is well within acceptable limits, demonstrating the product’s consistency and reliability. The publication of such test results supports harm reduction efforts and promotes informed decision-making for consumers.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
